ONWARD MEDICAL BUY | EUR17 It’s HemON!! H1 results in line and validation in sight
º Results in line with expectations with upside shown in catalyst timelinesWith clinical momentum building, we reiterate our Buy rating and EUR17 TP
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.